The use of comparative effectiveness research to inform policy decisions on the inclusion of bevacizumab for the treatment of macular diseases in Thailand's pharmaceutical benefit package

ClinicoEconomics and Outcomes Research

Volumn 4, Issue 1, 2012, Pages 361-374

  Anothaisintawee, Thunyarat ^a,b   Leelahavarong, Pattara ^a   Ratanapakorn, Tanapat ^c   Teerawattananon, Yot ^a  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Bevacizumab; Comparative effectiveness research; Diabetic macular edema; Macular degeneration; Retinal vein occlusion

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ACUTE HEART INFARCTION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; DIABETIC MACULAR EDEMA; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ENDOPHTHALMITIS; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; LASER COAGULATION; META ANALYSIS (TOPIC); PHOTODYNAMIC THERAPY; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULOPATHY; RETINA VEIN OCCLUSION; REVIEW; SYSTEMATIC REVIEW; THAILAND; TREATMENT RESPONSE; VISUAL ACUITY; VITREOUS HEMORRHAGE;

EID: 84870883422     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S37458     Document Type: Review

References (49)

1. Mohara A, Youngkong S, Pérez Velasco R, et al. Using health technology assessment for informing coverage decisions in Thailand. J Comp Eff Res. 2012;1(2):137-146.
2. Tarn YH, Hu S, Kamae I, et al. Health-care systems and pharmacoeconomic research in Asia-Pacific region. Value Health. 2008;11 Suppl 1: S137-S155.
3. Jirawattanapisal T, Kingkaew P, Lee TJ, Yang MC. Evidence-based decision-making in Asia-Pacific with rapidly changing health-care systems: Thailand, South Korea, and Taiwan. Value Health. 2009;12 Suppl 3:S4-S11.
4. Tantivess S, Teerawattananon Y, Mills A. Strengthening cost-effectiveness analysis in Thailand through the establishment of the health intervention and technology assessment program. Pharmacoeconomics. 2009;27(11):931-945.
5. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology. 2006;113(11):2002.e1-2002.e12.
6. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14): 1419-1431.
7. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36(4):331-335.
8. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444.
9. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57-65.e5.
10. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143(4):566-583.
11. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2005;36(4):336-339.
12. Jones G. Tracking demographic changes in Thailand and policy implications. In: Jones G, Im-em W, editors. Impact of Demographic Change in Thailand. Bangkok: Thai National Economic and Social Development Board and United Nations Population Funds; 2011.
13. Jenchitr W, Ruamviboonsuk P, Sanmee A, Pokawattana N. Prevalence of age-related macular degeneration in Thailand. Ophthalmic Epidemiol. 2011;18(1):48-52.
14. Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117(2):313-319.e1.
15. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556-564.
16. Campbell RJ, Dhalla IA, Gill SS, Bell CM. Implications of "not me" drugs for health systems: lessons from age related macular degeneration. BMJ. 2012;344:e2941.
17. Torjesen I. Novartis takes legal action over trusts' advice to use bevacizumab for wet AMD. BMJ. 2012;344:e2959.
18. Torjesen I. Why using Avastin for eye disease is so difficult. BMJ. 2012;344:e3012.
19. Bashshur ZF, Schakal A, Hamam RN, El Haibi CP, Jaafar RF, Noureddin BN. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol. 2007;125(10):1357-1361.
20. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2007;114(6):1179-1185.
21. Parodi MB, Iacono P, Papayannis A, Sheth S, Bandello F. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. Arch of Ophthalmol. 2010;128(4):437-442.
22. Sacu S, Michels S, Prager F, et al. Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results. Eye (Lond). 2009;23(12):2223-2227.
23. Biswas P, Sengupta S, Choudhary R, Home S, Paul A, Sinha S. Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration. Indian J Ophthalmol. 2011;59(3):191-196.
24. Gharbiya M, Giustolisi R, Allievi F, et al. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab - a randomized controlled trial. Am J Ophthalmol. 2010;149(3):458.e1-464.e1.
25. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-1908.
26. Subramanian ML, Abedi G, Ness S, et al. Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. Eye (Lond). 2010;24(11):1708-1715.
27. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010;117(6):1078.e2-1086.e2.
28. Scott IU, Edwards AR, Beck RW, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007;114(10):1860-1867.
29. Soheilian M, Ramezani A, Obudi A, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology. 2009;116(6):1142-1150.
30. Faghihi H, Roohipoor R, Mohammadi SF, et al. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol. 2008;18(6):941-948.
31. Solaiman KA, Diab MM, Abo-Elenin M. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema. Retina. 2010;30(10):1638-1645.
32. Kinge B, Stordahl PB, Forsaa V, et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study. Am J Ophthalmol. 2010;150(3):310-314.
33. Russo V, Barone A, Conte E, Prascina F, Stella A, Noci ND. Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina. 2009;29(4):511-515.
34. Tufail A, Patel PJ, Egan C, et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ. 2010;340:c2459.
35. Andriolo RB, Puga ME, Belfort Junior R, Atallah AN. Bevacizumab for ocular neovascular diseases: a systematic review. Sao Paulo Med J. 2009;127(2):84-91.
36. Schmucker C, Ehlken C, Hansen LL, Antes G, Agostini HT, Lelgemann M. Intravitreal bevacizumab (Avastin) vs ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review. Curr Opin Ophthalmol. 2010;21(3):218-226.
37. Schouten JS, La Heij EC, Webers CA, Lundqvist IJ, Hendrikse F. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2009;247(1):1-11.
38. Yilmaz T, Cordero-Coma M, Gallagher MJ, Teasley LA. Systematic review of intravitreal bevacizumab injection for treatment of primary diabetic macular oedema. Acta Ophthalmol. 2011;89(8):709-717.
39. Goyal S, Lavalley M, Subramanian ML. Meta-analysis and review on the effect of bevacizumab in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2011;249(1):15-27.
40. Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing Snellen visual acuity measurements. Retina. 2010;30(7):1046-1050.
41. Raftery J, Clegg A, Jones J, Tan SC, Lotery A. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol. 2007;91(9):1244-1246.
42. Subcommittee for Development of the National List of Essential Medicines. Agenda for "A systematic review of bevacizumab for macular diseases" Conducted by HITAP Research. Nonthaburi: Food and Drug Administration, Ministry of Public Health, Thailand; 2012.
43. Bureau of Drug Control, Food and Drug Administration, Thailand. National List of Essential Medicines (NLEM). Available from: http://www.nlem.in.th. Accessed October 14, 2012.
44. Thai Food and Drug Administration. http://www.fda.moph.go.th/eng/drug/index.stm.
45. Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology. 2010;117(11):2146-2151.
46. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615-625.
47. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1124.e1-1133.e1.
48. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1102.e1-1112.e1.
49. Moradian S, Faghihi H, Sadeghi B, et al. Intravitreal bevacizumab vs. sham treatment in acute branch retinal vein occlusion with macular edema: results at 3 months (Report 1). Graefes Arch Clin Exp Ophthalmol. 2011;249(2):193-200.